On January 29, the U.S. District Court of the District of New Jersey denied in part the defendant’s 12(b)(6) motion on fraud-based and misrepresentation claims against manufacturers of generic blood pressure drugs. The claims were part of a multidistrict litigation presented by patients and insurers alleging they suffered physical injury as well as economic damages caused by products contaminated with probable carcinogens. Specifically, plaintiffs argued the drugs are tainted with industrial byproducts such as NDMA and NDEA and cause cancer. The court dismissed claims against pharmacies and wholesalers for lack of sufficiency but gave plaintiffs the opportunity to amend.